+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

2019 Future of Hepatic Encephalopathy (HE) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

  • ID: 4749274
  • Report
  • 45 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • AlfaSigma SpA
  • Cosmo Pharmaceuticals NV
  • Gilead Sciences Inc
  • KannaLife Sciences Inc
  • MallInckrodt Plc
  • Spherium Biomed SL
  • MORE
The global demand for Hepatic Encephalopathy (HE) treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Hepatic Encephalopathy (HE) pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Hepatic Encephalopathy (HE) pipeline companies from advancing their products into Phase 3 or Phase 4.

Hepatic Encephalopathy (HE) Report Description

The 2019 pipeline study on Hepatic Encephalopathy (HE) pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Hepatic Encephalopathy (HE) pipeline compounds.

The Hepatic Encephalopathy (HE) pipeline guide presents information on all active drugs currently being developed for Hepatic Encephalopathy (HE). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Hepatic Encephalopathy (HE) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Hepatic Encephalopathy (HE) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Hepatic Encephalopathy (HE) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Hepatic Encephalopathy (HE) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Hepatic Encephalopathy (HE) pipeline report includes
  • An overview of Hepatic Encephalopathy (HE) disease including symptoms, causes, diagnosis and available treatment options is provided.
  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
  • Phase wise count of Hepatic Encephalopathy (HE) pipeline
  • Company wise list of Hepatic Encephalopathy (HE) pipeline
  • Mechanism of Action wise Hepatic Encephalopathy (HE) pipeline
For each pipeline candidate, the following details are provided:
  • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
  • Current status of development
  • Drug overview
  • Mechanism of Action
  • Pre-clinical and Clinical Trials/Results
  • Company Overview and Recent Developments
Reasons to Buy
  • The report is designed to help industry executives promote the success and continued growth of their organizations
  • Get clear understanding of the entire Hepatic Encephalopathy (HE) pipeline, with details on active projects
  • Stay ahead of the competition through comprehensive knowledge of Hepatic Encephalopathy (HE) pipeline progress
  • Get in detail information of each product with updated information on each project along with key milestones
  • Gain clear insights into companies participating in Hepatic Encephalopathy (HE) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
The report will be delivered in 2 working days.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AlfaSigma SpA
  • Cosmo Pharmaceuticals NV
  • Gilead Sciences Inc
  • KannaLife Sciences Inc
  • MallInckrodt Plc
  • Spherium Biomed SL
  • MORE
1.1 List of Tables
1.2 List of Figures

2. Global Hepatic Encephalopathy (HE) Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology

3. Executive Summary
3.1 Hepatic Encephalopathy (HE) Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase 1
3.2.4Phase 2
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase 3
3.3.2 Pre-registration
3.4 Companies involved in Hepatic Encephalopathy (HE) pipeline, H1- 2019
3.5 Mechanism of Action wise Hepatic Encephalopathy (HE) Pipeline Candidates

4 AlfaSigma SpA Hepatic Encephalopathy (HE) Pipeline Details
4.1 AlfaSigma SpA Business Profile
4.2 AlfaSigma SpA Hepatic Encephalopathy (HE) Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5 Cosmo Pharmaceuticals NV Hepatic Encephalopathy (HE) Pipeline Details
5.1 Cosmo Pharmaceuticals NV Business Profile
5.2 Cosmo Pharmaceuticals NV Hepatic Encephalopathy (HE) Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6 Ferring International Center SA Hepatic Encephalopathy (HE) Pipeline Details
6.1 Ferring International Center SA Business Profile
6.2 Ferring International Center SA Hepatic Encephalopathy (HE) Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7 Gilead Sciences Inc Hepatic Encephalopathy (HE) Pipeline Details
7.1 Gilead Sciences Inc Business Profile
7.2 Gilead Sciences Inc Hepatic Encephalopathy (HE) Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8 KannaLife Sciences Inc Hepatic Encephalopathy (HE) Pipeline Details
8.1 KannaLife Sciences Inc Business Profile
8.2 KannaLife Sciences Inc Hepatic Encephalopathy (HE) Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9 MallInckrodt Plc Hepatic Encephalopathy (HE) Pipeline Details
9.1 MallInckrodt Plc Business Profile
9.2 MallInckrodt Plc Hepatic Encephalopathy (HE) Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10 Spherium Biomed SL Hepatic Encephalopathy (HE) Pipeline Details
10.1 Spherium Biomed SL Business Profile
10.2 Spherium Biomed SL Hepatic Encephalopathy (HE) Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11 Synlogic Inc Hepatic Encephalopathy (HE) Pipeline Details
11.1 Synlogic Inc Business Profile
11.2 Synlogic Inc Hepatic Encephalopathy (HE) Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments

12 Umecrine Cognition AB Hepatic Encephalopathy (HE) Pipeline Details
12.1 Umecrine Cognition AB Business Profile
12.2 Umecrine Cognition AB Hepatic Encephalopathy (HE) Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments

13. Latest Hepatic Encephalopathy (HE) Drug Pipeline Developments, 2019

14. Appendix
14.1 About Us
14.2 Sources and Methodology
14.3 Contact Information
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AlfaSigma SpA
  • Cosmo Pharmaceuticals NV
  • Ferring International Center SA
  • Gilead Sciences Inc
  • KannaLife Sciences Inc
  • MallInckrodt Plc
  • Spherium Biomed SL
  • Synlogic Inc
  • Umecrine Cognition AB
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4749274
Adroll
adroll